Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has formed a strategic partnership with Microport in connection with a $43.4m round.

UT Southwestern has formed central nervous system diseases treatment developer Taysha Gene Therapies with executives who previously worked for OSU's Avexis.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

NetScientific's pre-tax loss was halved to $6.5m during 2019, and the firm also reported improved cash availability.

Boehringer Ingelheim Venture Fund co-led a series A round set to drive clinical work on UC Berkeley-founded Actym Therapeutics' immunotherapy pipeline.

Novo and Pivotal BioVenture Partners both invested as the lung disease therapy developer took its overall funding close to $100m.

Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.